Quipt Home Medical (QIPT) Proxy Filing summary

Executive summary

• Entered into a definitive arrangement agreement for acquisition at $3.65 per share in cash, subject to shareholder approval and other customary closing conditions.

• Hart-Scott-Rodino Act waiting period expired, satisfying a key regulatory condition for the transaction.

• Forward-looking statements caution on risks, including regulatory approvals, competing offers, and potential impacts on relationships.

Voting matters and shareholder proposals

• Shareholders will vote on the proposed acquisition as outlined in the arrangement agreement.

• Definitive proxy statement and management information circular will be sent to securityholders for voting decisions.

Board of directors and corporate governance

• Directors and executive officers may be considered participants in the proxy solicitation for the transaction.

• Information about directors and officers is available in the proxy statement for the Annual General Meeting.